# A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer

> **NCT00102895** · PHASE2 · TERMINATED · sponsor: **Pfizer** · enrollment: 25 (—)

## Conditions studied

- Breast Neoplasms
- Neoplasm Metastasis

## Interventions

- **DRUG:** CP-724,714

## Key facts

- **NCT ID:** NCT00102895
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2005-04
- **Primary completion:** —
- **Final completion:** 2005-09
- **Target enrollment:** 25 (—)
- **Why stopped:** See Detailed Description
- **Last updated:** 2010-08-27


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102895

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102895, "A Research Study of CP-724,714 in Patients With HER2 Overexpressing Metastatic Breast Cancer". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT00102895. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*